Kiefer F, Anhauser I, Soriano P, Aguzzi A, Courtneidge S A, Wagner E F
Research Institute of Molecular Pathology, Vienna, Austria.
Curr Biol. 1994 Feb 1;4(2):100-9. doi: 10.1016/s0960-9822(94)00025-4.
Expression of polyomavirus middle T antigen (PymT) rapidly induces endothelial tumors (hemangiomas) in mice, with an apparent single rate-limiting step. Because activation of Src-like kinases is thought to be an important component of PymT-induced transformation, we have analyzed the functional requirement for individual kinases in this process. This type of analysis has only recently become possible, with the generation of 'gene knock-out' mice lacking each of the kinase genes src, fyn and yes.
Hemangiomas develop efficiently in newborn mice lacking either src, fyn or yes after inoculation with a PymT-transducing retrovirus. In src- and fyn-deficient mice, the kinetics of induction and the histological properties of the tumors were indistinguishable from those in wild-type mice. In contrast, a reduced number of tumors arose in yes-deficient mice, with a significantly longer latency period. Transformed endothelial cell lines derived from the induced hemangiomas, however, did not differ in their morphological and tumorigenic properties from cell lines established previously from wild-type mice. Biochemical analysis of complexes between PymT and the Src-related kinases in these cell lines suggests that the Yes kinase is responsible for a significant amount of the PymT-associated kinase activity in transformed endothelial cells.
We have demonstrated that inactivation of a single tyrosine kinase of the Src family in endothelial cells does not abrogate PymT-induced hemangioma formation. As the remaining kinases do not compensate for the absence of a family member by elevated kinase activity, the loss--which affects the transformation process to varying degrees--can be studied in this model system. Our studies suggest that the PymT-Yes kinase complex plays a major role in the tumor-initiating action of PymT.
多瘤病毒中T抗原(PymT)的表达可在小鼠中迅速诱导内皮肿瘤(血管瘤)形成,且存在一个明显的单一限速步骤。由于Src样激酶的激活被认为是PymT诱导转化的重要组成部分,我们分析了该过程中单个激酶的功能需求。随着缺乏激酶基因src、fyn和yes的“基因敲除”小鼠的产生,这种类型的分析直到最近才成为可能。
接种PymT转导逆转录病毒后,缺乏src、fyn或yes的新生小鼠高效地发生血管瘤。在缺乏src和fyn的小鼠中,肿瘤诱导的动力学和组织学特性与野生型小鼠无异。相比之下,缺乏yes的小鼠中肿瘤数量减少,潜伏期显著延长。然而,源自诱导血管瘤的转化内皮细胞系在形态和致瘤特性上与先前从野生型小鼠建立的细胞系并无差异。对这些细胞系中PymT与Src相关激酶之间复合物的生化分析表明,Yes激酶在转化内皮细胞中负责大量与PymT相关的激酶活性。
我们已经证明,内皮细胞中Src家族单个酪氨酸激酶的失活并不消除PymT诱导的血管瘤形成。由于其余激酶不会通过升高的激酶活性来补偿家族成员的缺失,因此可以在该模型系统中研究这种缺失(其对转化过程有不同程度的影响)。我们的研究表明,PymT-Yes激酶复合物在PymT的肿瘤起始作用中起主要作用。